Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Satoru Hara"'
Autor:
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CM
Externí odkaz:
https://doaj.org/article/58f4e055c3eb45ed81510406b1170155
Autor:
Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Abstract For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment,
Externí odkaz:
https://doaj.org/article/d6cec3dbf9054fe0b643aba4e9c79cd9
Autor:
Kazuyuki Aihara, Kazuhisa Fujikawa, Mayuko Tsuda, Satoru Hara, Mitsuhito Hirano, Arinobu Tojo, Tadahiko Igarashi, Junichi Hisatake, Takeaki Sugawara, Shinji Nakaoka, Atsushi Shinagawa, Kaichi Nishiwaki, Toshiaki Yujiri, Shigehisa Tamaki, Hisashi Wakita, Kai Morino, Masashi Kajita, Kei-ji Sugimoto, Yuji Okamoto, Seiichi Shimizu, Hisayuki Yokoyama
Publikováno v:
NPJ systems biology and applications. 8(1)
Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase1,2. ABL1-selective tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML3–7. The ul
Autor:
Junichi Hisatake, Takeaki Sugawara, Shigehisa Tamaki, Kaichi Nishiwaki, Kazuhisa Fujikawa, Hisashi Wakita, Toshiaki Yujiri, Tadahiko Igarashi, Arinobu Tojo, Seiichi Shimizu, Satoru Hara, Atsushi Shinagawa, Keiji Sugimoto, Hisayuki Yokoyama
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment, nilotinib
Autor:
Keita Matsumoto, Atsushi Yamaguchi, Takahiro Oka, Masahiro Yasumoto, Satoru Hara, Michitaka Iida, Marek Teichmann
Publikováno v:
Proceedings of the 37th International Symposium on Automation and Robotics in Construction (ISARC).
Autor:
Satoshi Hamai, Satoru Harada, Hidetoshi Tsushima, Ryutaro Kozuma, Satoshi Yamate, Shinya Kawahara, Yukio Akasaki, Tetsunari Harada, Yasuhiko Kokubu, Toshiki Konishi, Yasuharu Nakashima
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract No report has clarified the frequency and interacting factors affecting sleep disturbance among Asian patients at midterm after total knee arthroplasty (TKA). This study aimed to evaluate the frequency of sleep disturbance at midterm after T
Externí odkaz:
https://doaj.org/article/fbbef97445104a5bb81cbfb3bc07730b
Autor:
Ryuko Cho, Masahiro Onoda, Hiroaki Tanaka, Nobuyuki Aotsuka, Yusuke Isshiki, Emiko Sakaida, Chikako Ohwada, Takeharu Kawaguchi, Akira Yokota, Takeaki Sugawara, Motoharu Fukazawa, Satoru Hara
Publikováno v:
Japanese Journal of Clinical Oncology. 47:1047-1054
Background The efficacy of conventional chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been controversial as post-remission therapies for adult Philadelphia chromosome-negative acute lymphoblastic leukemia patient
Autor:
Taeko Uehara, Akira Yokota, Megumi Ejiri, Miki Nishimura, Yasushi Saito, Satoru Hara, Chiaki Nakaseko, Akane Harima
Publikováno v:
American Journal of Hematology. 76:368-372
Chronic active Epstein-Barr virus infection (CAEBV) is a heterogeneous EBV-related disorder, ranging from mild/moderate forms to rapidly lethal disorders. The lethal form of CAEBV is characterized by multiple organ failure, hemophagocytic syndrome, a
Autor:
Tsutomu Numata, Satoru Hara, Norio Shimizu, Kazuhiro Kurasawa, Ittaku Mikata, Akiyoshi Konno, Miki Nishimura, Kohtaro Yamamoto, Hiroshi Nagata
Publikováno v:
Pathology International. 51:778-785
Chronic active Epstein–Barr virus infection (CAEBV) is a syndrome that takes diverse clinical courses and is often associated with lymphoproliferative disorders of T / natural killer (NK)-cell lineage. We describe a patient with CAEBV associated wi
Autor:
Kazuhisa Fujikawa, Satoru Hara, Tadahiko Igarashi, Keiji Sugimoto, Arinobu Tojo, Takeaki Sugawara, Junichi Hisatake, Kaichi Nishiwaki, Shigehisa Tamaki, Yujiri Toshiaki, Atsushi Shinagawa, Hisashi Wakita, Seiichi Shimizu, Hisayuki Yokoyama
Publikováno v:
Blood. 128:1925-1925
Background : Nilotinib is a potent and selective inhibitor of BCR-ABL. In the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) trial, frontline nilotinib therapy at 300 mg twice daily (BID) resulted in a